Pay in 4 interest-free payments of $6.33 Learn more
Ships within 48 hours · Estimated delivery Sep 9 - Sep 14
With the FDA announcing that Eli Lillys popular weight loss drug, Tirzepatide, is no longer in shortage and clarifying its policies on compounding GLP-1 receptor agonists, these changes could influence MedSpa operations, patient care, and the broader healthcare landscape
Current Clinical Evidence: What Studies Actually Show Controlled trials using semaglutide or tirzepatide for diabetes and weight loss have documented mood and cognitive effects as secondary observations, not primary endpoints
The 2018 meta-analysis on chitosan showed a modest 1 kg weight loss, but many studies were of low quality, and the results werent always consistent
Tirzepatide additionally activates GIP receptors, which may contribute to its effects on appetite and metabolism
NPs with FPA can prescribe independently, including controlled substances (with consultation agreements for Schedule II opioids)
US$ 29.01
US$ 24.47
US$ 24.13
US$ 25.79
US$ 29.25
US$ 28.53
US$ 21.65
US$ 25.19
US$ 21.84
US$ 20.90
US$ 20.07
